Anti-factor Xa activity of enoxaparin administered at prophylactic dosage to patients over 75 years old (Q36102602)

12 August 2017

Anti-factor Xa activity of enoxaparin administered at prophylactic dosage to patients over 75 years old (English)

1 reference

12 August 2017

A Berges

1

1 reference

12 August 2017

S Laporte

2

1 reference

12 August 2017

M Epinat

3

1 reference

12 August 2017

P Zufferey

4

1 reference

12 August 2017

E Alamartine

5

1 reference

12 August 2017

B Tranchand

6

1 reference

12 August 2017

H Decousus

7

1 reference

12 August 2017

P Mismetti

8

1 reference

12 August 2017

PROPHRE.75 Study Group

9

1 reference

12 August 2017

language of work or name

English

0 references

publication date

17 May 2007

1 reference

British Journal of Clinical Pharmacology

12 August 2017

1 reference

12 August 2017

64

1 reference

12 August 2017

4

1 reference

12 August 2017

428-438

1 reference

A new equivalence based metric for predictive check to qualify mixed-effects models

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2048556

Administration of enoxaparin by continuous infusion in a naturalistic setting: analysis of renal function and safety.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2048556

Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2048556

Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2048556

Principles and clinical application of assessing alterations in renal elimination pathways.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2048556

Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2048556

Development of a dosing strategy for enoxaparin in obese patients

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2048556

Low-molecular-weight heparins: are they all the same?

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2048556

Impact of omission or replacement of data below the limit of quantification on parameter estimates in a two-compartment model

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2048556

Use of LMW heparin: information for prescribers. Update: 10 April 2002

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2048556

How and when to monitor a patient treated with low molecular weight heparin

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2048556

A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2048556

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2048556

Estimating population kinetics.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2048556

Prediction of creatinine clearance from serum creatinine

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2048556

Estimating impossible curves using NONMEM.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2048556

A size standard for pharmacokinetics.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2048556

A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2048556

Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2048556

Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2048556

Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery

2 July 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2007.02920.X

Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2007.02920.X

Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2007.02920.X

Effect of renal function on the pharmacokinetics of enoxaparin and consequences on dose adjustment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2007.02920.X

Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2007.02920.X

Renal function in the elderly (>70 years old) measured by means of iohexol clearance, serum creatinine, serum urea and estimated clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2007.02920.X

Allometric relationships between the pharmacokinetics of propofol in rats, children and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2007.02920.X

Enoxaparin in unstable angina patients with renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2007.02920.X

Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2007.02920.X

The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparine low molecular weight heparin to prevent deep vein thrombosis after hip replacement.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2048556

A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients

23 September 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2007.02920.X

Aging and heparin-related bleeding

21 January 2018

1 reference

12 December 2020

Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin)

1 reference

12 December 2020

Elderly medical patients treated with prophylactic dosages of enoxaparin: influence of renal function on anti-Xa activity level

1 reference

12 December 2020

Optimal low-molecular-weight heparin regimen in major orthopaedic surgery. A meta-analysis of randomised trials

1 reference

12 December 2020

10.1111/J.1365-2125.2007.02920.X

Identifiers

DOI

1 reference

12 August 2017

1 reference

12 August 2017

1 reference